Single-arm, Open-label, Interventional Study to Observe the Safety and Efficacy Profile of the Combined Oral Contraceptive YAZ, a 24-day Cyclic Regimen Containing Drospirenone 3 mg and Ethinyl Estradiol 20 µg During a Treatment Duration of 6 Cycles: a Post-authorization Safety and Efficacy Study in Chinese Women
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Drospirenone/ethinylestradiol (Primary)
- Indications Pregnancy
- Focus Adverse reactions
- Sponsors Bayer
- 29 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Feb 2017 Planned End Date changed from 1 Aug 2018 to 1 Jul 2018.
- 19 Feb 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Jul 2018.